source
- Mark Cuban's Cost Plus Drugs targets rare disease market with custom n-of-1 therapiesMark Cuban's Cost Plus Drugs, known for low-cost generics, is expanding into rare disease treatments. The company has dedicated part of its new manufacturing plant to producing custom "n-of-1" the…
- Biotech reverse mergers surge in 2026, reaching highest level since 2021 as PIPE financing spikesBiotech companies are using reverse mergers to re‑enter public markets at a rate not seen since 2021, according to a J.P. Morgan report released in October 2026. In the first nine months of 2026,…